PRESS RELEASE
22 March 2018

BioInvent researchers co-publish article in Cancer Cell on mechanism of action of anti-CTLA-4 antibodies

Lund, Sweden – 22 March 2018 – BioInvent International AB (OMXS: BINV)

In next issue of Cancer Cell, and online today, researchers from University College in London publish translational data demonstrating that the activity of clinically validated anti-CTLA-4 antibodies depends, at least in part, on the depletion of tumour-infiltrating Treg cells. The research group, which is led by BioInvent collaborator Professor Sergio Quezada, further demonstrated that intratumoural Treg depletion was dependent on interactions between human IgG antibodies and Fc-gamma receptors. Enhanced antibody-dependent cell-mediated cytotoxicity, either by Fc optimization, or the presence of Fc-gamma receptors variants with high binding affinity, improves therapeutic outcomes, but only in highly immunogenic tumours.

The findings that are presented in this paper support the notion that modulation of Fc gamma receptor binding may be an attractive strategy to improve activity of CTLA-4 antibodies, and potentially antibodies directed against additional targets with high relative expression on Treg cells.

BioInvent researchers contributed to this paper by helping determine expression and function of antibody interactions with Fc gamma receptors on tumour-infiltrating immune cells.

Reference
Vargas FA, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Aissa AB, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B, TRACERx Melanoma, TRACERx Renal and TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA. **Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies** *Cancer Cell*
DOI: https://doi.org/10.1016/j.ccell.2018.02.010

Notes to editors:

About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI- 1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB- 403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December 2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late- stage clinical trials. More information is available at www.bioinvent.com

For further information, please contact:
Björn Frendéus
Acting CEO and CSO
+46 (0) 46 286 25 45
+46 (0) 708 11 25 45
bjorn.frendeus@bioinvent.com

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.